x

Company Overview

RVAC Medicines is an mRNA platform company. We are building a diverse pipeline of innovative medicines. Our leading asset, a COVID-19 vaccine, is quickly moving into clinical trials and is well-positioned to serve emerging markets in regions that are struggling with vaccine access, where we are rapidly establishing regional manufacture capabilities. Our company has built its team with top-tier scientists and established key partnerships to leverage clinically validated technologies. Incubated by the CBC Group, RVAC Medicines is headquartered in Singapore with R&D centers in Boston and Shanghai.

MORE +

Management Team

RVAC Medicines is built with strong leaders with key specialization in mRNA design, immunology, vaccines, nucleic acid delivery, manufacturing, clinical development, regulatory sciences, and commercialization.

Scientific Advisory Board

We are working with the world’s leading scientists in mRNA biology, immunology, vaccines, and nucleic acid delivery technologies.

Professor Nigel Slater

Professor Nigel Slater

Professor Rongjun Chen

Professor Rongjun Chen

Mingzi

zhiwei

x

Copyright RVAC Medicines All rights reserved 2022

Terms of use